Isto Biologics

What Isto Biologics does

Isto Biologics is a privately held, pure-play biologics medical device company headquartered in Hopkinton, Massachusetts, founded in 1997. The company develops and manufactures orthobiologic solutions for bone healing and regeneration, organized into three product families: autologous concentration systems (Magellan and Precise with CellectFlex technology) that process patient blood into PRP, concentrated bone marrow aspirate, and platelet poor plasma; allograft products (the Influx family — ProteiOS, Fibrant, SPARC, PLUS, Sponge — plus OsseoGen) derived from donor tissue; and synthetic bone grafts (InQu). The company targets orthopedic surgeons and physicians through an enterprise field sales model, complemented by direct rep contact systems, website quote requests, and clinical content (publications, references, patents). Revenue mechanics are device and consumable sales (hardware plus single-use kits) and allograft/synthetic product SKUs sold into surgical practices, hospitals, and through distributor partners.

The company has grown through serial M&A, acquiring Progenicare (2017), TheraCell (2022), and merging with California-based Advanced Biologics/Biologica Technologies (2023), integrating OsseoGen and ProteiOS into its allograft portfolio. Ownership transitioned from Thompson Street Capital Partners to Keensight Capital, which acquired a majority stake in October 2025. The company operates through multiple wholly-owned subsidiaries (Arteriocyte Medical Systems, Isto Technologies II, Progenicare, Progenicare Therapeutics, Advanced Transfusion Services), employs 101-250 people, and competes in the global orthobiologics market valued at $5.4B in 2021 with projected ~7% annual growth through 2026. Pricing is quote-based and not publicly disclosed; management includes Brian Barnes (CEO), Davis Adkisson (CSO), Nathan Taylor (President), and Jerry Keefe (VP Operations).

Name

Isto Biologics

Legal name

Company, Inc.

Website

http://istobiologics.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Isto Biologics is a private, pure-play orthobiologics medical device company that develops and sells autologous concentration systems, allograft products, and synthetic bone grafts to orthopedic surgeons, physicians, and distributors for bone healing and regeneration procedures.

Ownership category

akta.pro rank

Product category

Orthobiologics & Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)

Keywords

• Orthobiologic solutions
• Autologous concentration systems
• Bone graft substitutes
• Spine biologics
• Medical device manufacturing

Headquarters

HQ city

Hopkinton

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Autologous Therapies: Sale of Magellan and Precise autologous concentration systems and associated kits for creating PRP and concentrated bone marrow aspirate therapies.
2. Allograft Products: Sale of various allograft product lines including Influx, ProteiOS, Fibrant, SPARC, PLUS, Sponge, and OsseoGen derived from donor tissue for bone grafting procedures.
3. Synthetic Bone Grafts: Sale of InQu biosynthetic bone graft products offering cell-friendly bone fusion solutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Isto Biologics develops, manufactures, and commercializes orthobiologic medical devices and tissue-based products used in spine and orthopedic surgery. Its portfolio spans autologous point-of-care concentration systems (Magellan), bone marrow aspiration kits with proprietary CellectFlex technology (Precise line), specialty needles (Lightning Needle), and a range of allograft, synthetic, and biosynthetic bone graft substitutes (Influx line, OsseoGen, InQu) that surgeons use to support bone fusion and healing.

Differentiator

Problem solved

Functional benefit

Brands

• Magellan: Magellan Autologous Concentration System - market leading autologous concentration device for creating PRP, Concentrated Bone Marrow Aspirate, and Platelet Poor Plasma
• Precise
• Lightning Needle
• Influx
• InQu
• ProteiOS
• OsseoGen
• Precise Diamond
• Precise Sapphire

Products and services

• Magellan Autologous Concentration System
• Precise Bone Marrow Aspiration Kit
• Lightning Needle
• Influx Product Line
• OsseoGen
• InQu Biosynthetic Bone Graft

Quantifiable outcome

• InQu biosynthetic bone graft outperforms fusion rates of ICBG (Iliac Crest Bone Graft)
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Advanced BiologicscoreStrategic or Co-development Partner · 18 October 2023Advanced Biologics, also known as Biologica Technologies, merged with Isto Biologics in October 2023. The merger integrated Advanced Biologics' proprietary products including OsseoGen and ProteiOS into Isto's portfolio, combining clinical, research, and commercial expertise.
• TheraCellminorStrategic or Co-development Partner · 5 April 2022Isto Biologics acquired TheraCell to expand its regenerative therapy capabilities. TheraCell was integrated into Isto's biologics portfolio.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Arthrex: A privately held, large orthopedics and sports medicine company with a broad orthobiologics portfolio including allografts, PRP systems, and bone graft substitutes. Arthrex competes directly with Isto in surgeon-targeted biologics for orthopedic and sports medicine procedures.
• Globus Medical: Spine-focused medical device company with a growing orthobiologics portfolio including bone graft substitutes and regenerative products. Directly comparable to Isto in the spine biologics segment and now combined with NuVasive.
• Orthofix Medical: Spine and orthopedics company with a dedicated biologics portfolio including bone graft solutions and regenerative products. Comparable to Isto as a focused player in orthobiologics with overlapping surgeon call points.
• Bioventus: Pureplay orthobiologics company offering bone graft substitutes, hyaluronic acid injections, and regenerative therapies. Directly comparable to Isto as a focused biologics competitor in bone healing and joint preservation.
• SeaSpine: Spine-focused medical device company with a meaningful orthobiologics portfolio including allograft and synthetic bone graft substitutes. Comparable to Isto in spinal fusion and orthopedic biologics markets.
• MTF Biologics: Non-profit tissue bank and orthobiologics manufacturer with a broad portfolio of allograft products for bone, cartilage, and soft tissue repair. Comparable to Isto as a tissue-derived biologics supplier serving orthopedic surgeons.

Broad incumbents

• Medtronic: Global medical device leader with a significant spine and biologics franchise, including the Infuse bone graft (rhBMP-2) product. Medtronic competes with Isto in spinal fusion biologics and broader orthobiologic applications as part of a much wider implant portfolio.
• Stryker: Major orthopedic medtech company offering bone graft substitutes, allografts, and regenerative products within its orthopedics and spine portfolio. Competes with Isto across multiple biologics categories and has substantially greater scale and sales reach.
• DePuy Synthes (Johnson & Johnson MedTech): Orthopedics and spine franchise of J&J MedTech offering bone grafts and regenerative solutions as part of a comprehensive orthopedic portfolio. Competes with Isto in trauma, spine, and reconstructive orthobiologics markets.
• Zimmer Biomet: Global orthopedic device manufacturer with a biologics portfolio spanning bone grafts and regenerative products. Competes with Isto across orthopedic reconstructive, sports medicine, and trauma biologics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCtu3EDFsT5_GdwOj8iOFg1g
• LinkedInlinkedin.com/company/isto-biologics
• Facebookfacebook.com/2162872590701921

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Isto Biologics